Monitoring of serum concentrations of posaconazole given as prophylaxis or therapy.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2008-007712-14-BE

Enrollment

Registered

2009-01-07

Start date

2009-01-17

Completion date

Unknown

Last updated

2022-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fungal infection MedDRA version: 9.1 Level: LLT Classification code 10017533 Term: Fungal infection

Interventions

Trade Name: Noxafil Pharmaceutical Form: Oral suspension INN or Proposed INN: posaconazole CAS Number: 171228-48-2 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentra

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients receiving posaconazole as prophylaxis of fungal infection and patients treated with posaconazole for a fungal infection. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: No exclusion criteria

Design outcomes

Primary

Measure	Time frame
Main Objective: To evaluate the serum concentrations of posaconazole in patient treated prophylacticaly or as therapy of a fungal infection;Secondary Objective: To determine the factors which influence these concentrations;Primary end point(s):	—

Countries

Belgium

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026